No profile data available.
Kura Oncology, Inc. (KURA) is a healthcare company in the blood cancer treatment drugs industry, based in San Diego, United States, with about 260 full-time employees.
It reported revenue of $67.48 million for fiscal year 2025, up 25.2% from fiscal year 2024, and net income of -$278.67 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $20.87 million, up 36.5% from a year before. Its market capitalization was $942.98 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Kura Oncology reported $67.48 million in revenue for fiscal year 2025, up 25.2% from $53.88 million in fiscal year 2024. In Q2 2026 revenue was $20.87 million.
$942.98 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Sellas Life Sciences Group, Inc. (SLS), Ascentage Pharma Group International (AAPG), Vor Biopharma Inc. (VOR), Corvus Pharmaceuticals, Inc. (CRVS).